Vpriv
Pfizer Gaucher drug rejected by CHMP
June 25, 2012Sales and Marketing Elelyso, FDA, Gaucher, Pfizer, Shire, Vpriv
A European committee has refused marketing authorisation for Pfizer’s Gaucher disease drug Elelyso, as a competitor drug has exclusivity to …
Pfizer enters Gaucher disease market
May 3, 2012Sales and Marketing Cerezyme, Elelyso, Gaucher, Genzyme, Pfizer, Shire, Vpriv
Pfizer has gained FDA approval for its new Gaucher disease drug Elelyso. Elelyso (taliglucerase alfa) is an enzyme replacement therapy …
Shire’s Vpriv website in breach of ABPI Code
April 24, 2012Medical Communications, Sales and Marketing ABPI, Genzyme, PMCPA, Shire, Vpriv, code
Shire’s website for its Gaucher’s disease drug Vpriv has fallen foul of the ABPI’s Code of Conduct. The complaint was …
Shire’s Vpriv plant wins EU approval
February 28, 2012Manufacturing and Production EMA, Shire, Vpriv
Shire has been told by the European Medicines Agency that it can make use of a manufacturing facility in Lexington, …
Robust sales for Shire
February 13, 2012Sales and Marketing Replagal, Shire, Vpriv, Vyvanse
A rise in the use of attention deficit and hyperactivity disorder drugs has helped push Shire’s turnover past $4 billion …
Shire facility could answer rare disease drug shortage
November 27, 2011Manufacturing and Production Fabry disease, Gaucher, Shire, Vpriv
Shire has filed applications with the European and US regulators to produce its Gaucher disease drug Vpriv (velaglucerase alfa) at …
Shire gets green light for second Replagal facility
June 28, 2011Manufacturing and Production Replagal, Shire, Vpriv, pharma manufacturing news
The European Medicines Agency has approved a second manufacturing facility in the USA for Shire’s Fabry disease treatment Replagal. Shire’s …
Shire says new plant will add to Replagal, Vpriv capacity
January 17, 2011Manufacturing and Production Cerezyme, Replagal, Shire, Vpriv
UK drugmaker Shire has completed construction of a new manufacturing facility for its orphan disease drugs Replagal and Vpriv, and …
Pfizer submits Gaucher drug to EMA
November 29, 2010Sales and Marketing Cerezyme, EMA, Gaucher disease, Genzyme, Pfizer, Protalix BioTherapeutics, Shire, Vpriv, taliglucerase alfa
Pfizer and partner Protalix BioTherapeutics have submitted a marketing application to European regulator the EMA for their Gaucher disease candidate …
Shire readies Gaucher drug Vpriv
February 23, 2010Manufacturing and Production Cerezyme, Gaucher's, Shire, Vpriv
Shire Pharmaceuticals says it has already manufactured enough of its Vpriv to treat around 400 Gaucher disease patients and could …
